宫内生长迟缓胎儿脐血IGF-Ⅰ及IGFBP-3水平观察

目的：探讨新生儿脐血中胰岛素样生长因子-I（IGF-I）和胰岛素样生长因子结合蛋白-3（IGFBP-3）水平与胎儿宫内生长发育的关系。方法：采用放射免疫分析,分别对出生时体重正常新生儿与宫内生长迟缓的低体重新生儿脐血的IGF-I及IGFBP-3水平进行检测。结果：宫内发育迟缓组新生儿脐血的IGF-I及IGFBP-3的含量明显低于正常对照组（P〈0.01）,有显著差异性。结论：：IGF-I和IGFBP-3与胎儿宫内生长发育密切相关,对胎儿的宫内生长发育起着重要的调节作用。     

IGF-I与宫内发育迟缓及其结合蛋白的关系

目的：检测宫内发育迟缓（IUGR）儿脐血胰岛素样生长因子-I（IGF-I）、胰岛素样生长因子结合蛋白-3（IGFBP-3）水平,分析这些指标的变化程度与胎儿期生长的关系。方法：将86例脐血标本分为IUGR（即小于胎龄儿）组和适于胎龄儿（AGA）组。采用放射免疫分析（RIA）测定IGF-I水平,免疫放射分析（IR-MA）测定IGFBP-3水平。两组间比较用t检验,两变量之间的关系采用相关回归分析。结果：与AGA组相比,IUGR组脐血IGF-I和IGFBP-3水平显著降低（P均〈0.01）;IGF-I、IGFBP-3均随胎龄及出生体重增加而增加（P均〈0.01）;IGFBP-3与IGF-I呈正相关（P〈0.01）。结论：脐血IGF-I和IGFBP-3的含量可作为判断新生儿生长发育程度的一项客观指标。     

IGF-I及其在疾病治疗中的作用

IGF-I是胰岛素样生长因子的家族成员之一,与胰岛素有相似结构,可促进许多细胞的生长和增殖。IGF-I几乎存在于机体的每一个系统中，具有多种生物学活性，是临床上重要的生长因子,许多疾病都和IGF-I的缺乏或过量有关。本文介绍了IGF-I基因的结构特点及遗传生化特性，综述了IGF-I在疾病治疗中作用的最新研究进展。     

重组人生长激素辅助治疗儿童特发性矮小症的临床疗效及安全性研究

目的:研究重组人生长激素辅助治疗儿童特发性矮小症的临床疗效及安全性.方法:回顾性分析2020年1月～2022年05月期间我院收治的80例特发性矮小症患儿为研究对象.根据治疗方法的不同将其分为治疗组(n=40)和对照组(n=40).对照组采用常规营养治疗并补充维生素D、钙和维生素B12;研究组在对照组的基础上采用重组人生长激素辅助治疗.比较两组临床疗效、生长情况(身高、生长速率、骨龄)、生长因子[胰岛素样生长因子(Insulin-like Growth Factors,IGF-I)、胰岛素样生长因子结合蛋白-3(Nsulin-like growth factor binding protein3,IGFBP-3)]水平及不良反应发生率.结果:治疗前两组生长情况比较无明显差异(P>0.05),治疗后两组患者身高、生长速率、骨龄均出现上升,其中研究组身高、生长速率显著高于对照组(P<0.05),但两组骨龄比较差异不具有统计学意义(P>0.05).治疗前两组患者IGF-I、IGFBP-3水平比较无明显差异(P>0.05),治疗后两组患者IGF-I、IGFBP-3水平均出现上升,其中研究组上升程度更为显著(P<0.05).对照组不良反应发生率为2.5％,研究组不良反应发生率为5.0％,两组比较差异不具有统计学意义(P>0.05).结论:重组人生长激素辅助治疗儿童特发性矮小症的临床疗效显著,可有效提高患儿体内IGF-I、IGFBP-3水平,且安全性较高.     

小柴胡汤治疗大鼠子宫内膜异位症作用机制的实验研究

通过建立大鼠子宫内膜异位症(内异症)动物模型, 利用免疫组化的方法, 观察分析各用药组在位、异位内膜Fas及Caspase-3蛋白的表达, 探讨小柴胡汤治疗大鼠内异症的作用机制.结果显示, 小柴胡汤治疗组内异症大鼠异位内膜Fas蛋白、Caspase-3蛋白的表达水平明显高于其在位内膜, 而对照组中却恰恰相反, 丹那唑组中两者相差不明显, 提示小柴胡汤治疗大鼠内异症的作用机制可能是通过上调Fas蛋白的表达, 促进异位内膜细胞的凋亡而实现的.     

不同T细胞亚群及与其他免疫细胞协同作用参与子宫内膜异位病灶的形成和发展

子宫内膜异位症(简称:内异症)是育龄期妇女常见的妇科疾病,虽然内异症的发病机制至今尚未完全阐明,但越来越多的证据表明免疫因素在内异症的发病中具有重要作用。内异症患者盆腹腔异常的免疫微环境是子宫内膜得以异位种植生长的关键因素。T细胞在细胞免疫反应中居于核心地位,不同T细胞亚群则发挥着不同的免疫效应功能,它们与其他免疫细胞如单核巨噬细胞、树突细胞、自然杀伤细胞等协同作用,共同参与内异症的发生发展。     

卵巢局部IGF-I系统与多囊卵巢综合征胰岛素抵抗的相关性研究

目的：研究卵巢局部胰岛素样生长因子-I系统（IGF-I系统）在伴有胰岛素抵抗多囊卵巢综合征中的作用机制。方法选择30例合并胰岛素抵抗的PCOS（polycystic ovary syndrome）患者为试验组,30例患有卵巢良性肿瘤需手术探查的患者为对照组。检测并对比血清、小卵泡液中IGF-I、胰岛素样生长因子结合球蛋白-1（IGFBP-1）与各项性激素,FI,2hI,ISI,QUICK I,卵巢超声指标,研究其与各种指标间的相关性。结果试验组小卵泡液IGF-I高于对照组（P〈0.01）,小卵泡液及血清IGFBP-1低于对照组（P〈0.05,P〈0.01）。试验组小卵泡液IGF-I水平高于血清（P〈0.01）,小卵泡液IGFBP-1水平低于血清（P〈0.05）。试验组小卵泡液IGF-I与T0、E2及卵巢体积（OV）,卵巢总面积（TA）,卵泡数（FN）,空腹胰岛素（FI）,服糖后2h胰岛素（2hI）呈正相关（P〈0.05）;血清IGF-I与胰岛素敏感指数（ISI）,体重指数（BMI）,腰臀比（WHR）呈正相关（P〈0.05）,与定量胰岛素敏感指数（QUICK I）呈负相关（P〈0.05）;试验组小卵泡液及血清IGFBP-1与FI,2hI呈负相关（P〈0.05）。结论 IR可能通过影响卵巢局部IGF-I系统,刺激卵巢分泌雄激素,引发排卵障碍,在PCOS的发病机制中起到重要作用。     

深部浸润性子宫内膜异位症的研究进展

子宫内膜异位症(内异症)有多种病理类型,不同类型具有不同的发病机制。深部浸润性内异症是指异位灶浸润深度超过5mm,其严重程度与盆腔疼痛及深部性交痛密切相关,因而得到越来越多的重视。本文综述近年来有关深部浸润性内异症研究进展的相关文献。     

肺癌患者血清IGF-I和IGFBP-3的表达及其临床意义

本文用免疫放射分析,测定肺癌患者血清中胰岛素样生长因子-I（IGF-I）和胰岛素样生长因子结合蛋白-3（IGFBP-3）的浓度,探讨其在肺癌诊断中的应用价值。     

胰岛素样生长因子结合蛋白-4在结直肠肿瘤中的研究进展

结直肠癌是最常见的消化系统癌症之一,其晚期或转移性肿瘤患者的预后仍然很差。而胰岛素样生长因子结合蛋白4(IGFBP-4)是一种多功能的细胞增殖调控因子,具有IGFBP结构域和甲状腺球蛋白I型结构域,其在骨骼发育、细胞增殖、信号转导以及调控细胞生长方面发挥着重要的作用,并且参与生物体的衰老过程以及多种疾病的发生。在结直肠肿瘤中,IGFBP-4既可通过与胰岛素样生长因子(IGF)结合发挥抑制肿瘤细胞增殖、分化以及生长,又可通过Wnt/β-catenin、IL-6、Bcl-2/Bax等多种信号通路参与结直肠肿瘤发生与发展过程。因此,本研究就近年关于IGFBP-4结构功能以及其与结直肠肿瘤发生关系的研究进展进行分析和总结。     

Identification of insulin-like growth factor (IGF)-I and IGF-binding protein in chylous ascites.

Insulin-like growth factors (IGFs) are bound by several IGF-binding proteins (IGFBPs) that appear to regulate IGF transportation, receptor binding and action. In adult human serum, most of IGFs are bound in a 150 kDa complex which could not cross the capillary wall. We measured IGF-I and IGFBPs in chyle by radioimmunoassay and western ligand blot. The concentration of IGF-I in chyle was only 15% of the corresponding serum level and most of IGF-I was found in 50 kDa complex. The IGFBPs profile in chyle, especially IGFBP-3, was different from that of serum. The concentration of IGFBP-3 in chyle was much less than in serum and the size of glycosylated IGFBP-3 was different from that of serum. However, the size and relative amount of IGFBP-1 and -2 in chyle were similar to serum. This finding indicates that IGF-I and IGFBPs in chyle to a large extent originate in the vascular system and only the 50 kDa complex can cross the capillary barrier.     

Serum and tissue level of insulin-like growth factor-I (IGF-I) and IGF-I binding proteins as an index of pancreatitis and pancreatic cancer

Previously we have found deregulation of collagen metabolism in human pancreatitis and pancreatic cancer tissues. Insulin-like growth factor-I (IGF-I) is known to stimulate collagen biosynthesis through interaction with IGF-I receptor. IGF-I binding proteins (BPs) regulate the activity of IGF-I. We investigated whether serum and tissue IGF-I and IGF-BPs as well as tissue IGF-I receptor expression may reflect disturbances of collagen metabolism in patients with pancreatitis and pancreatic cancer. In pancreatitis tissue, a significant increase in IGF-I and IGFBP-3 content was accompanied by a distinct increase in IGF-I receptor expression, compared to control pancreas tissue. In contrast, serum from patients with pancreatitis did not show significant increases in IGF-I and IGFBP-3 levels, however, significant increases in IGFBP-1 level (2.5 fold). Moreover, a distinct decrease in radioactive IGF-binding to the BPs, compared to control serum, was found. Pancreatic cancer tissue and serum of patients with pancreatic cancer showed significant increases in IGF-I, IGFBP-3 and IGFBP-1 content, accompanied by dramatic increases in IGF-I tissue receptor expression, compared to controls. In serum of patients with pancreatic cancer distinct increases in radioactive IGF-binding to 46 kDa BP, compared to control serum, were observed. The data suggest that disturbances in tissue collagen metabolism during pancreatic diseases may result from deregulation of IGF-I homeostasis and that elevated serum levels of IGF-I, IGFBP-3 and IGFBP-1 may serve as markers of pancreatic cancer.     

Expression, content, and localization of insulin-like growth factor I in human achilles tendon

In animals insulin-like growth factor I (IGF-I) stimulates collagen production by fibroblasts and is expressed in tendons together with its binding protein 4 (IGFBP-4). However, the presence of IGF-I and IGFBP-4 in human tendon tissue is not described. Tissue IGF-I content was examined by immunoflourometric assay, real-time PCR, and immunohistochemistry used to localize and determine expression of IGF-I and IGFBP-4 in 6 postmortem human Achilles tendons. Tendon tissue concentrations of IGF-I were found to be 0.53 +/- 0.10 ng/g. Furthermore, we demonstrated that IGF-I and IGFBP-4 are localized around the tendon fibroblasts and that mRNA for IGF-I and IGFBP-4 can be determined in human tendon tissue. The present study adds support for the roles of IGF-I and IGFBP-4 in the regulation of tendon adaptive responses to mechanical loading.     

Expression,Content, and Localization of Insulin-Like Growth Factor I in Human Achilles Tendon

In animals insulin-like growth factor I (IGF-I) stimulates collagen production by fibroblasts and is expressed in tendons together with its binding protein 4 (IGFBP-4). However, the presence of IGF-I and IGFBP-4 in human tendon tissue is not described. Tissue IGF-I content was examined by immunoflourometric assay, real-time PCR, and immunohistochemistry used to localize and determine expression of IGF-I and IGFBP-4 in 6 postmortem human Achilles tendons. Tendon tissue concentrations of IGF-I were found to be 0.53 ± 0.10 ng/g. Furthermore, we demonstrated that IGF-I and IGFBP-4 are localized around the tendon fibroblasts and that mRNA for IGF-I and IGFBP-4 can be determined in human tendon tissue. The present study adds support for the roles of IGF-I and IGFBP-4 in the regulation of tendon adaptive responses to mechanical loading.     

Insulin-like growth factor (IGF)-I and IGF binding protein-3 concentrations in fluid from human stimulated follicles

Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 (IGFBP- 3) play an important role in regulating follicle growth and maturation. We have evaluated whether responsiveness to gonadotrophins during an in- vitro fertilization (IVF) treatment is related to follicular fluid IGF- I and IGFBP-3 concentrations. We also investigated if a difference is present in IGF-I and IGFBP-3 concentrations between patients treated with human menopausal gonadotrophin (HMG) and patients treated with highly purified follicle stimulating hormone (FSH). We have measured IGF-I and IGFBP-3 in follicular fluid from pre-ovulatory follicles in an IVF programme. All 70 patients were stimulated after being down- regulated with a gonadotrophin-releasing hormone (GnRH) analogue. IGF-I concentrations in follicular fluid were significantly inversely correlated with the number of ampoules FSH administered and number of days of FSH administration, and significantly correlated with the number of follicles aspirated. IGFBP-3 concentrations were not correlated with any other parameter measured nor were IGF-I and IGFBP-3 concentrations correlated. IGFBP-3 concentrations were significantly higher in patients receiving highly purified FSH compared with patients receiving HMG (P < 0.005). These results are new evidence that IGF-I concentration in follicular fluid is higher in women who respond better to follicular stimulation, i.e. women who grow many follicles, women who need a shorter duration of stimulation and women who need fewer ampoules FSH before oocyte retrieval.      

Insulin-like growth factors and their binding proteins in human follicular fluid.

Increasing evidence suggests that insulin-like growth factors I and II (IGF-I, IGF-II) have a regulatory role in animal granulosa cells. This study was undertaken to investigate the presence of IGF-I and IGF-II, as well as that of their binding proteins (BP), IGFBP-1 and IGFBP-3 in human serum and follicular fluid (FF). Preovulatory FF was obtained from 51 patients undergoing in-vitro fertilization. The IGFBP-1 level was found to be significantly higher (P less than 0.01) in FF than in serum, whereas IGF-I and IGFBP-3 values remained markedly lower (P less than 0.01) in FF. Serum IGF-II levels were slightly but not significantly elevated compared to values obtained in the FF of patients. A positive correlation (P less than 0.001) between individual serum and FF levels was observed only for IGF-I. When a group of poor responders was compared to patients with normal stimulation characteristics, no significant difference was found in either IGF or IGFBP levels in the FF. It is concluded that IGFBP-1 is produced locally, whereas the serum may possibly be the major source of IGF-I. No clear conclusions can be drawn regarding the source of FF IGF-II and IGFBP-3. Neither the absolute level nor the relationship of IGFs to their transport proteins could explain the poor response to ovarian stimulation.     

Insulin-like growth factor binding protein-1 inhibits the DNA amplification induced by insulin-like growth factor I in human granulosa-luteal cells.

In order to study the effects of insulin-like growth factor (IGF-I) and insulin-like growth factor binding protein (IGFBP-1) on human granulosa cell proliferation after in vitro fertilization, cells were obtained after oocyte retrieval and cultured in the presence or absence of graded amounts of recombinant IGF-I, purified IGFBP-1 and [3H]thymidine. Physiological concentrations of IGF-I (2-200 ng/ml) were found to stimulate [3H]thymidine incorporation into the cells in a concentration-dependent manner. Half-maximal stimulation of [3H]thymidine incorporation was obtained with 10 ng/ml exogenous IGF-I, which was chosen for suppression experiments with graded amounts of purified IGFBP-1. Suppression of IGF-stimulated thymidine incorporation was observed when 200 ng/ml or more of IGFBP-1 was added to the culture medium. The same concentration of IGFBP-1 also markedly inhibited binding of [125I]iodotyrosyl IGF-I to the cells. It is concluded that: (i) after a refractory period, granulosa cells from hyperstimulated follicles retained their mitogenic activity; (ii) IGF-I is capable of stimulating DNA amplification in granulosa cells; and (iii) IGFBP-1 inhibits the IGF-I stimulated proliferation in these cells. In view of our previous studies showing that IGFBP-1 is synthesized by the granulosa cells as they luteinize, the present results suggest that IGFBP-1 is one of the endogenous factors locally regulating the growth and differentiation of granulosa cells.